Key clinical point: PARP inhibitors may improve progression-free survival compared with hormonal agents in men with metastatic castration-resistant prostate cancer.

Major finding: Median radiographic progression-free survival was 7.39 months with olaparib vs. 3.55 months with enzalutamide or abiraterone.

Study details: Randomized open-label phase 3 trial of 387 men with metastatic castration-resistant prostate cancer bearing homologous recombination repair alterations.

Disclosures: The PROfound trial was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and Merck. Dr. Hussain disclosed travel and/or accommodation support, honoraria, consulting/advisory fees and research support from AstraZeneca and others. Dr. Duran disclosed advisory board fees from Roche and BMS, and speaker honoraria from Roche, Bristol-Myers Squibb, and Merck. Dr. Efstathiou disclosed research support and honoraria from various companies, not including AstraZeneca or Merck.